medigraphic.com
Instituto Nacional de Salud Pública

2005, Number 3

<< Back Next >>

salud publica mex 2005; 47 (3)

Influenza vaccination in the elderly population in Mexico: Economic considerations.

Gutiérrez JP, Bertozzi SM

Language: Spanish
References: 23
Page: 234-239
PDF size: 118.25 Kb.


ABSTRACT

Objective. To estimate costs and health outcomes that could be attained by an influenza vaccination program in adults 65 years of age and older in Mexico. Material and methods. Between June and October 2004, a model was constructed to estimate the number of life years lost due to influenza and the fraction that could be prevented by vaccination among adults 65 years of age and older. The model also allowed the estimation of the net cost of a vaccination program, including both the cost of delivering the vaccine and savings from prevented infections and their treatment costs. Results. Using two scenarios of vaccine effectiveness, between 7 454 and 11 169 life years could saved by the vaccine if given to all adults 65 years and older in Mexico, with a net cost per life year saved between 13 301 and 21 037 Mexican pesos (about $1 210 and $1 910 US dollars). Discussion. Influenza vaccination among the elderly in Mexico would result in savings per life year saved well below the Mexican gross domestic product (GDP) per capita, suggesting, even without examining alternative uses for these resources, that this is a cost effective intervention in Mexico and probably also in other middle-income developing countries.


REFERENCES

  1. Secretaría de Salud. Principales causas de mortalidad en edad posproductiva (65 años y más) 2001. Sistema Nacional de Información en Salud. Disponible en: http://www.salud.gob.mx/apps/htdocs/estadisticas/egresoshosp/danossalud.htm [2004 junio 17].

  2. Secretaría de Salud. Sistema Nacional de Vigilancia Epidemiológica, Epidemiología, Semana 16, México, DF: Secretaría de Salud; 2004.

  3. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization

  4. Practices (ACIP). MMWR Morb Mortal Wkly Rep Recomm Rep 2004 May 28;53(RR-6):1-40.

  5. Ayora-Talavera G, Góngora-Biachi RA, López-Martínez I, Moguel-Rodríguez W, Pérez-Carrillo H, Vázquez-Zapata V et al. Detection of human influenza virus in Yucatan, Mexico. Rev Invest Clin 2002; 54(5):410-414.

  6. World Health Organization. Influenza vaccines: WHO position paper: Wkly Epidemiol Rec 2002;77:230-240.

  7. Estadística de egresos hospitalarios del sector público del Sistema Nacional de Salud, 2003. Salud Publica Mex 2004; 46(5):464-487.

  8. Consejo Nacional de Población. Proyecciones de la población de México, 2000-2050. México, DF: Conapo; 2002.

  9. Murray CJL, López, AD, ed. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard University Press; 1996. (Global Burden of Disease and Injury Series, Vol. 1).

  10. Lozano AR, Gómez FS, Herrera BE, Sousa FA, Avila-Figuero C. Estimación de los costos de producción de servicios clínicos para la prevención, diagnóstico y tratamiento médico en el sistema de salud mexicano. México, DF: Secretaría de Salud; 2003.

  11. World Health Organization. Comission. Macroeconomics and health: Investing in health for economic development. Report of the Comission on Macroeconomics and health. Ginebra: World Health Organization; 2001.

  12. World Health Organization. The World Health Report 2002 – Reducing risks, promoting healthy life. Ginebra: World Health Organization; 2002.

  13. Secretaría de Salud. Principales causas de mortalidad en edad posproductiva (65 años y más) 2001. Sistema Nacional de Información en Salud. Disponible en: http://www.salud.gob.mx/apps/htdocs/estadisticas/egresoshosp/danossalud.htm [2004 junio 17].

  14. Secretaría de Salud. Sistema Nacional de Vigilancia Epidemiológica, Epidemiología, Semana 16, México, DF: Secretaría de Salud; 2004.

  15. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization ractices (ACIP). MMWR Morb Mortal Wkly Rep Recomm Rep 2004 May 28;53(RR-6):1-40.

  16. Ayora-Talavera G, Góngora-Biachi RA, López-Martínez I, Moguel-Rodríguez W, Pérez-Carrillo H, Vázquez-Zapata V et al. Detection of human influenza virus in Yucatan, Mexico. Rev Invest Clin 2002; 54(5):410-414.

  17. World Health Organization. Influenza vaccines: WHO position paper: Wkly Epidemiol Rec 2002;77:230-240.

  18. Estadística de egresos hospitalarios del sector público del Sistema Nacional de Salud, 2003. Salud Publica Mex 2004; 46(5):464-487.

  19. Consejo Nacional de Población. Proyecciones de la población de México, 2000-2050. México, DF: Conapo; 2002.

  20. Murray CJL, López, AD, ed. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard University Press; 1996. (Global Burden of Disease and Injury Series, Vol. 1).

  21. Lozano AR, Gómez FS, Herrera BE, Sousa FA, Avila-Figuero C. Estimación de los costos de producción de servicios clínicos para la prevención, diagnóstico y tratamiento médico en el sistema de salud mexicano. México, DF: Secretaría de Salud; 2003.

  22. World Health Organization. Comission. Macroeconomics and health: Investing in health for economic development. Report of the Comission on Macroeconomics and health. Ginebra: World Health Organization; 2001.

  23. World Health Organization. The World Health Report 2002–Reducing risks, promoting healthy life. Ginebra: World Health Organization; 2002.




2020     |     www.medigraphic.com